- New Kisqali® (ribociclib)* overall survival (OS) results from MONALEESA-2 trial in HR+/HER2− advanced breast cancer patients in the first-line setting
- Health-related quality of life, pain and safety outcomes from phase III VISION trial of investigational radioligand therapy 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
- Data supporting upcoming regulatory filings for tislelizumab in people with squamous and non-squamous non-small cell lung cancer (NSCLC), and for alpelisib in people with PIK3CA-Related Overgrowth Spectrum (PROS)
- Novartis to host virtual panel on access to quality cancer care in Europe, open to ESMO registered participants, as part of the company’s ongoing support for #EUnite initiative
San Francisco, CA (UroToday.com) — Novartis will present new data from its robust portfolio and pipeline of advanced therapeutic platforms in solid tumors, with more than 55 abstracts from Novartis-sponsored and investigator-initiated trials accepted at the upcoming European Society for Medical Oncology (ESMO) Congress 2021. The ESMO Congress will be held virtually September 16-21, 2021.